TICKERNERD
Menu
SPROSPROHealthcare · Biotechnology

SPRO Stock Forecast: Spero Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.13
+0.89% on the day

The 1 Wall Street analysts covering Spero Therapeutics, Inc. hold a median 12-month price target of $4 — +254.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 11 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$65.2M
Ticker Nerd rank
83 / 100
Median analyst target
$4.00
Analysts covering
1
Revenue$0.0−100.0% y/y
Operating income−$9.9M
Net income−$9.6M
Free cash flow−$5.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.4%
1M
−8.1%
YTD
−51.5%
1Y
−42.1%
From 52W high
−62.1%
From 52W low
+0.9%
$1.12
$2.98
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SPRO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Spero Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
100
Value
99
Accruals
89
Size
80
Issuance
74
Quality
57
Volatility
45
Revisions
29
Momentum
16

Growth (100): Sales and profits are climbing, and climbing faster than before.

Momentum (16): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SPRO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPRO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26SPROHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +254.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 Jan 2025HC Wainwright & Co.ReiteratesBuy$5.00
20 Dec 2024Evercore ISI GroupDowngradeIn-Line—
2 Dec 2024HC Wainwright & Co.ReiteratesBuy—
18 Nov 2024TD CowenDowngradeHold—
15 Nov 2024Cantor FitzgeraldReiteratesOverweight—
4 Nov 2024HC Wainwright & Co.MaintainsBuy—
3 Oct 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024Cantor FitzgeraldReiteratesOverweight—
6 Aug 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024TD CowenUpgradeBuy—
16 May 2024HC Wainwright & Co.ReiteratesBuy—
4 Apr 2024Cantor FitzgeraldReiteratesOverweight—
18 Mar 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2023HC Wainwright & Co.ReiteratesBuy—
5 Sept 2023HC Wainwright & Co.ReiteratesBuy—
14 Aug 2023HC Wainwright & Co.MaintainsBuy—
1 Aug 2023HC Wainwright & Co.ReiteratesBuy—
20 July 2023HC Wainwright & Co.ReiteratesBuy—
10 Apr 2023HC Wainwright & Co.ReiteratesBuy—
26 Sept 2022HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPRO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SPRO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Spero Therapeutics, Inc. returned −42.1% against +17.5% for the S&P 500, dividends included.

SPRO vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26SPROS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SPRO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−143.3%
Analysts raising
0
Analysts cutting
0
Fundamentals

Spero Therapeutics, Inc. (SPRO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
8.6×

Cheaper than 61% of US stocks

Price / sales
1.4×

Cheaper than 62% of US stocks

Price / book
1.5×

Cheaper than 56% of US stocks

EV / EBITDA
2.1×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
14.1%

Higher than 71% of US stocks

Net margin
15.7%

Higher than 78% of US stocks

Returns & dividend
Return on equity
19.2%

Higher than 80% of US stocks

Return on assets
7.2%

Higher than 86% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Spero Therapeutics, Inc. (SPRO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Spero Therapeutics, Inc. has a market value of $65.2M and an enterprise value of $16.5M.

  • Revenue in the twelve months to 30 June 2026: $43.0M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: $7.4M, a 17.2% net margin.

  • Diluted earnings per share, trailing twelve months: $0.11.

  • Free cash flow in the twelve months to 30 June 2026: $19.6M.

  • Shares outstanding: 58.1M.

  • Trailing P/E: 8.6×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Spero Therapeutics, Inc. employs 25 people — $1.7M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

SPRO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPROSpero Therapeutics, Inc.$65.2M
83
ELOXEloxx Pharmaceuticals, Inc.$63.6M
13
BOLDBoundless Bio, Inc.$63.4M
84
LONALeonaBio, Inc.$64.4M
40
DWTXDogwood Therapeutics, Inc.$65.9M
37
HYFTMindWalk Holdings Corp.$60.9M
58
XBITXBiotech, Inc.$66.8M
31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Spero Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SPRO news & analysis

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 3 Sept 2026neutral

Spero Therapeutics announced that its Compensation Committee approved an inducement grant on September 1, 2026, consisting of 102,000 restricted stock unit awards and 67,600 stock options for new employees under the company's 2019 Inducement Equity Incentive Plan.

Why it matters — SPRO watchers may care because this routine equity grant is part of the company's standard employee incentive program and signals new hires joining the biopharmaceutical firm.

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 2 Sept 2026neutral

Spero Therapeutics announced that its President and Chief Executive Officer, Esther Rajavelu, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made on September 2, 2026.

Why it matters — A SPRO watcher would care because the CEO's presentation at a major investment conference offers an opportunity for the company to communicate its clinical-stage programs in immunology and inflammation to investors.

Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Spero Therapeutics published the transcript of its Q2 2026 earnings call on Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and management commentary.

Why it matters — SPRO watchers can review the earnings call transcript for management's detailed discussion of the company's quarterly performance and outlook.

Spero Therapeutics Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026positive

Spero Therapeutics used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate planned for initial development in IgG4-related disease.

Why it matters — The update signals a new strategic direction for Spero, with a recent FDA approval and a new licensing deal marking notable near-term developments for the company.

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

GlobeNewsWire · 12 Aug 2026neutral

Spero Therapeutics, a clinical-stage biopharmaceutical company focused on immunology and inflammation, announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The announcement was made on August 12, 2026.

Why it matters — SPRO watchers would care because the quarterly results and corporate update provide key insights into the company's financial standing and pipeline progress.

FAQ

Frequently asked questions about SPRO stock

What is the SPRO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Spero Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPRO stock a buy right now?

Of the 1 analysts covering Spero Therapeutics, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spero Therapeutics, Inc. 83 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPRO?

As at 11 Sept 2026, Spero Therapeutics, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).

Will SPRO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +254.0% from the last close, and Ticker Nerd's factor model ranks Spero Therapeutics, Inc. 83 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPRO stock forecast for 2030?

No analyst covering Spero Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has SPRO stock performed over the past year?

Spero Therapeutics, Inc. returned -42.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Spero Therapeutics, Inc. do?

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases.

What is the latest news on SPRO?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)". Spero Therapeutics announced that its Compensation Committee approved an inducement grant on September 1, 2026, consisting of 102,000 restricted stock unit awards and 67,600 stock options for new employees under the company's 2019 Inducement Equity Incentive Plan.

Company

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero Therapeutics advances a pipeline of product candidates aimed at serious infectious and immune-mediated conditions, including tebipenem pivoxil, an oral carbapenem antibiotic for complicated urinary tract infections, SPR720 for nontuberculous mycobacterial pulmonary disease, SPR206 for difficult Gram-negative infections, and SP001 for immune-mediated disease. The company’s work centers on addressing high unmet medical needs in hospital, outpatient, and specialty care settings through novel small-molecule and biologic therapies. Headquartered in Cambridge, Massachusetts, Spero Therapeutics plays a role in the biopharmaceutical market by focusing on differentiated medicines for patients with limited treatment options.

CEO Ms. Esther P. Rajavelu · 25 employees · United States · https://sperotherapeutics.com